Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

European Journal of Cancer

Volumn 37, Issue 1, 2001, Pages 97-105

  Erba, E ^a   Bergamaschi, D ^a   Bassano, L ^a   Damia, G ^a   Ronzoni, S ^a   Faircloth, G T ^b   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PharmaMar USA Inc   (United States)

Author keywords

Cell cycle; DNA repair; DNA interacting drug; Ecteinascidin 743; Natural product

Indexed keywords

CYCLIN A; CYCLIN B1; DNA; NATURAL PRODUCT; PROTEIN P53; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL SYNCHRONIZATION; CONTROLLED STUDY; DNA DETERMINATION; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; INTESTINE CARCINOMA; MARINE ENVIRONMENT; PRIORITY JOURNAL;

ECTEINASCIDIA TURBINATA;

EID: 0035146702     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00357-9     Document Type: Article

References (30)

1. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
2. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata
3. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)
4. In vitro schedule dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
5. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
6. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
7. A phase I and pharmacokinetic trial of ecteinacidin-743 (ET-743) administered as a 72 hour continuous infusion
8. Final results of phase 1 study of ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts)
9. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
10. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata
11. Characterisation of antimitotic products from marine organisms that disorganise the microtuble network: Ecteinascidin 743, isohomohalichondrin-B and LL-15
12. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove
13. Recent progress with the DNA repair mutants of Chinese hamster ovary cells
14. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line
15. Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts
16. Characterization of cyclin B1 expression in human cancer cell lines by a new three-parameter BrdUrd/cyclin B1/DNA analysis
17. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry
18. Measurement of strand breaks and cross-links by alkaline elution
19. NMR-based model of an ecteinascidin 743-DNA adduct
20. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
21. Pharmacokinetics (PK) of Ecteinascidin-743 (ET-743) in three different phase I trials
22. Pharmacokinetics (PK)/pharmacodynamic (PD) relationships in patients (PT) treated with Ecteinascidin-743 (ET-743) given as 24 hours (h) continuous infusion (CI)
23. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents
24. Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA
25. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin
26. The major adduct of antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by ∼40° toward the major groove
27. Interference of transcriptional activation by the anti-neoplastic drug ET-743
28. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
29. Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line
30. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair